| N° of patients |
129 |
37 |
|
| Males, N° (%) |
91 (70.5) |
30 (81.1) |
0.20 |
| Age, years, median (IQR) |
40.9 (37.2–44.2) |
41.0 (38.0–44.3) |
0.85 |
| BMI, m2/kg, median (IQR) |
22.8(21.2–24.86) |
23.6 (21.5–25.4) |
0.72 |
|
Nadir of CD4+, cell/mmc, median (IQR)
|
258.0 (165.25–422.0) |
272.0 (149.0–374.0) |
0.82 |
| Past IVDU, N°(%) |
77 (59.6) |
23 (72.2) |
0.93 |
| HIV RNA, cps/mL, median (IQR) |
8321.0 (1541.5–36329.8) |
12000.0 (3183.5–31052.0) |
0.19 |
| HIV RNA Negative (< 50 cps /mL), N° (%) |
55 (42.6) |
11 (35.1) |
0.16 |
| HIV RNA Positive (≥ 50 cps /mL), N° (%) |
65 (50.4) |
23 (62.2) |
|
CD4+, cell/mmc, median (IQR)
|
509.5 (404.5–691.0) |
466.0 (355.0–608.5) |
0.37 |
|
CD4+ ≤ 500 cell/mmc, N° (%)
|
59 (45.7) |
21 (56.8) |
0.25 |
|
CD4+
> 500 cell/mmc, N° (%)
|
69 (53.5) |
16 (43.2) |
| AST, IU/mL, median (IQR) |
54.0 (38.3–77.0) |
112.0 (76.0–166.5) |
0.0000016 |
| ALT, IU/mL, median (IQR) |
72.0 (43.5–120.0) |
137.0(87.5–223.5) |
0.00039 |
| Bilirubin, mg/dL, median (IQR) |
0.7 (0.49–1.05) |
0.8 (0.4–1.1) |
0.7 |
| GGT, IU/mL, median (IQR) |
68.5 (33.0–155.3) |
99.0 (60.0–189.0) |
0.06 |
| ALP, IU/mL, median (IQR) |
179.0 (132.0–238.3) |
205.0 (177.0–274.0) |
0.008 |
| Glucose, mg/dL, median (IQR) |
87.0 (79.0–95.0) |
91.0 (83.3–99.8) |
0.0153 |
| Creatinine, mg/dL, median (IQR) |
0.78 (0.7–0.9) |
0.8 (0.7–0.8) |
0.64 |
| Triglycerides, mg/dL, median (IQR) |
127.0 (86.5–169.8) |
123.0 (169.75–182.0) |
1 |
| Total cholesterol, mg/dL, median (IQR) |
163.0 (137.0–194.0) |
154.0 (121.5–180.5) |
0.53 |
|
HCV RNA, IUx103, median (IQR)
|
511250.0 (115550.0–1432735.0) |
732000 (342000.0–1487013.0) |
0.30 |
| Duration of HIV infection, years, median (IQR) |
14.4 (7.7–18.1) |
13.3 (7.5–18.3) |
0.37 |
| ART-treated, N°(%) |
103 (82.2) |
28 (75.7) |
0.58 |
| ART-naïve, N°(%) |
26 (20.2) |
9 (24.3) |
| Duration of ART, years, median (IQR) |
8.2 (6.2–11.3) |
6.79 (4.46–10.3) |
0.2 |
| CB2-63 QQ, N° (%) |
23 (17.8) |
3 (8.1) |
0.01 |
| CB2-63 QR, N° (%) |
55 (42.6) |
9 (24.3) |
| CB2-63 RR, N° (%) |
51 (47.3) |
25 (65.6) |
| HCV genotype 1, N° (%) |
47 (38.2) |
14 (37.8) |
0.19 |
| HCV genotype 2, N° (%) |
7 (5.7) |
1 (2.7) |
| HCV genotype 3, N° (%) |
48 (39.0) |
20 (54.0) |
| HCV genotype 4, N° (%) |
21 (17.1) |
2 (5.4) |
| HCV genotype missing, N° |
6 |
0 |
| Liver histology: |
|
|
|
| Fibrosis, score (M ± SD) |
1.9± 1.4 |
3.6± 1.5 |
0.00000068 |
| Fibrosis score 0–3, N° (%) |
114 (88.4) |
22 (67.6) |
0.0001 |
| Fibrosis score 4–6, N° (%) |
15 (11.6) |
15 (40.5) |
| Steatosis, score (M ± SD) |
1.6 ± 1.3 |
2.0 ± 1.3 |
0.03 |
| Steatosis score 0–2, N° (%) |
91 (70.5) |
19 (51.3) |
0.03 |
| Steatosis score 3–4, N° (%) |
38 (29.5) |
18 (48.7) |
